Mostrar el registro sencillo del ítem

dc.contributor.author
Sosnik, Alejandro Dario  
dc.date.available
2017-03-29T18:38:14Z  
dc.date.issued
2010-08  
dc.identifier.citation
Sosnik, Alejandro Dario; Nanotechnology contributions to the pharmacotherapy of pediatric HIV: a dual scientific and ethical challenge and a still pending agenda; Future Medicine; Nanomedicine; 5; 6; 8-2010; 833-837  
dc.identifier.issn
1743-5889  
dc.identifier.uri
http://hdl.handle.net/11336/14456  
dc.description.abstract
The Human Immunodeficiency Virus (HIV)/Acquired Immunodeficiency Syndrome (AIDS) is the most deadly infectious disease of our times. It currently affects more than 40 million people worldwide [101]. HIV is a disease of poverty as more than 80% of the patients live in developing nations and 60% in the sub-Saharan region (sSR) of Africa. Children represent approximately 6% of the infected population, though 15% of the new infections and the 15% of the nearly 2 million annual deaths. In addition, 15 million children have been orphaned due to AIDS [102]; 11.6 millions only in the sSR. Pediatric HIV has been almost eradicated in developed countries by preventing the mother-to-child-transmission (MTCT) and replacing natural delivery by caesarean. Conversely, in the developing world, 1000 new cases are registered every day. Only 10% of the HIV-positive children have appropriate access to medication, this extent decreasing dramatically to less than 2% in the sSR [103]. Thus, while HIV is gradually becoming a chronic and manageable disease in Europe and North America owing to the high activity antiretroviral therapy (HAART) or cocktail, most HIV-infected children in Africa are unfortunately sentenced to die before the two years of age.  
dc.format
application/pdf  
dc.language.iso
eng  
dc.publisher
Future Medicine  
dc.rights
info:eu-repo/semantics/openAccess  
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/  
dc.subject
Cost-Viable Liquid Formulations  
dc.subject
Efavirenz  
dc.subject
Ethical Affordability  
dc.subject
Neglected Diseases  
dc.subject
Pediatric Hiv  
dc.subject
Scalable Liquid Formulations  
dc.subject.classification
Otras Nanotecnología  
dc.subject.classification
Nanotecnología  
dc.subject.classification
INGENIERÍAS Y TECNOLOGÍAS  
dc.title
Nanotechnology contributions to the pharmacotherapy of pediatric HIV: a dual scientific and ethical challenge and a still pending agenda  
dc.type
info:eu-repo/semantics/article  
dc.type
info:ar-repo/semantics/artículo  
dc.type
info:eu-repo/semantics/publishedVersion  
dc.date.updated
2017-03-21T20:12:42Z  
dc.journal.volume
5  
dc.journal.number
6  
dc.journal.pagination
833-837  
dc.journal.pais
Reino Unido  
dc.journal.ciudad
Londres  
dc.description.fil
Fil: Sosnik, Alejandro Dario. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Tecnología Farmacéutica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina  
dc.journal.title
Nanomedicine  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/http://www.futuremedicine.com/doi/10.2217/nnm.10.64  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.2217/nnm.10.64